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Numerous Western studies have shown a negative correlation between height and
cardiovascular disease. However, these correlations do not prove causation. This review
provides a variety of studies showing short people have little to no cardiovascular disease.
When shorter people are compared to taller people, a number of biological mechanisms
evolve favoring shorter people, including reduced telomere shortening, lower atrial fibril-
lation, higher heart pumping efficiency, lower DNA damage, lower risk of blood clots, lower
left ventricular hypertrophy and superior blood parameters. The causes of increased heart
disease among shorter people in the developed world are related to lower income, exces-
sive weight, poor diet, lifestyle factors, catch-up growth, childhood illness and poor envi-
ronmental conditions. For short people in developed countries, the data indicate that
a plant-based diet, leanness and regular exercise can substantially reduce the risk of
cardiovascular disease.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction increased in parallel with increasing height during the 20thIn 2010, a meta-analysis of 52 studies found that short people
had higher rates of coronary heart disease (CHD).1 The nega-
tive correlation between height and CHD is basically correct.
However, this correlation does not prove that short height
promotes CHD per se and some researchers have attributed
the findings to other factors. For example, Tuomilehto2 eval-
uated the Paajanen study1 and concluded that there are too
many conflicting findings to conclude that short height is
biologically related to CHD. He points to several paradoxes;
e.g., between 1900 and 1970, CHD in Finland increased in
parallel with increasing height. Also, in most populations,
women are shorter than men and have lower CHD. In addi-
tion, Wells3 reported that cardiovascular disease (CVD) has2013, Cardiological Sociecentury. Furthermore, the World Cancer Research Fund and
American Institute of Cancer Research4 found that the
Western diet promotes increased height and CVD, stroke and
other chronic diseases. In addition, Tuomilehto2 and Silven-
toinen5 reported that the Western diet was correlated with
both greater height and CVD.
The following provides a counter view to the Paajanen
findings1 including a variety of examples from interna-
tional studies showing that shorter people have lower
incidence of CVD. In addition, the biological mechanisms
for this low incidence of CVD are reviewed. The informa-
tion provided is not widely known among the medical
profession and provides a fresh view of CVD risk in relation
to body height.ty of India. All rights reserved.
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The PubMed database was searched using MeSH terms: body
height and coronary disease/mortality and cardiovascular
disease/mortality. Papers were evaluated for findings related
to lower coronary and cardiovascular mortality. In addition,
a file of over 5000 papers, reports and books was searched for
populations with low coronary and cardiovascular mortality.
These paperswere collected over 37 years as a part of research
related to health, longevity, and other factors related to the
ramifications of smaller human and animal body size.3. Results
During the 20th century, numerous studies found that short
populations in traditional societies have little to no CVD. A
sampling of examples showing shorter people have low CVD
mortality are included in this section. This section concludes
with the biological advantages of shorter height in relation to
CVD.
3.1. Neutral findings
A number of studies indicate that neither tall nor short people
have increased risk of CVD. These neutral studies were based
on United Kingdom, South Korean, international, and US
cohorts (Hosegood and Campbell,6 Kannam,7 Samaras,8 Song
and Sung,9 Song,10 and Liao11). A number of other studies have
also failed to find a significant correlation between height and
CVD.12
3.2. Findings showing shorter people have lower CVD
mortality or risk factors
Table 1 provides examples showing shorter people have low
or no CHD or stroke. Table 1 consists of longitudinal, cross-
sectional, ecological and descriptive studies. In addition, the
examples include a variety of ethnic groups, geographical
locations and diets. A few examples, such as the Solomon
Islanders, US California ethnic groups, Belfast vs. Toulouse,
and the island of Kitava are summarized next.
3.2.1. Absence of CVD in the Solomon Islands
Page21 evaluated the CVD risk factors of 1390 adults in six
different Solomon Island societies. The physical health and
nutrition of these societies were good and no clinical evidence
of CHD and atherosclerosis was found. Males 20 years and
older averaged 161 cm and 58.8 kg. Their average BMI was
22.7 kg/m2. Physical fitness was excellent based on their
ability to carry heavy loads uphill for many miles.
3.2.2. Lower CHD among shorter Californians and Western
Europeans
A study of 1 million deceased Californians found that the
shortest ethnic groups (Chineseand Japanese)had substantially
lower risk of CHD mortality than the tallest (Blacks and
Whites).12 Latinos andAsian Indianswere in between these two
groups in terms of height and CHD. These data were comparedwith eleven Western European countries. While the ethnicities
differed, the pattern of reduced CHD mortality with reduced
heightwas basically the same; e.g., the taller N. Europeanmales
had higher CHD mortality vs. shorter S. European males.
Mortality rates for the tallest Californians (Whites and Blacks)
and Scandinavians were roughly the same aswere the rates for
the Chinese and Japanese in California vs. the Spanish and
Portuguese in Europe. The tallest men in California and N.
Europe were about the same height as were the heights of the
shorter Japanese, Chinese, Spanish and Portuguese.
3.2.3. CVD comparison between Belfast and Toulouse
The CHD and stroke mortality rates between 400 men in Bel-
fast, N. Ireland and 400 men in Toulouse, France were evalu-
ated22 for males 45e54 years of age. CHDwas 4 times higher in
taller Belfast males vs. shorter Toulouse males. Stroke was up
to 2.1 times higher in Belfast males. Belfast males were
173.3 cm and 78.9 kg vs. 171.1 cm and 76.4 kg for Toulouse
males (personal correspondence, E. McCrum, PhD, unpub-
lished data, 5/11/2000).
3.2.4. Absence of CHD and stroke in Kitava
Lindeberg23 evaluated the cardiovascular risk factors in awell-
nourished traditional Melanesian population located on the
island of Kitava. The study included 151 males and 69 females
aged 14e87 years, and the population was essentially free of
Western dietary habits. This 10-year study found no evidence
of stroke and CHD based on interviews, clinical experience,
and resting electrocardiography. About 80% of the adults
smoked and were moderately active (activity levels were
about the same level of comparable Swedish cohorts). Kitava
males averaged w161 cm from 20 to 86 years and females
averaged 150 cm. Male body mass indexes (BMIs) fell from 22
to 19 with increasing age while female BMIs declined from 20
to 17 with increasing age. These findings are consistent with
previous studies that found no CHD or atherothrombotic
stroke in all of Papua New Guinea.24 These findings covered
a 70-year period and were based on clinical investigations and
autopsy studies.
3.2.5. Support from centenarian and canine studies
Most studies find that centenarians are usually short and
lean even when adjusted for shrinkage with age.15 It is
doubtful that many people can reach 100 years of age with
bad hearts. For example, an area in Sardinia made up of 14
municipalities is identified as the Blue Zone and has the
highest longevity in Sardinia and mainland Italy (Poulain,13
Salaris25). The people in the Blue Zone are the shortest and
also have the lowest CVD mortality in Sardinia.13 Longevity
was also found to increase with decreasing height. In
summary, short Blue Zone males had the best long-term
survival rates and the lowest CVD mortality in Sardinia. A
recent study based on Western Sicilians also found that
centenarians were short and free of cardiac risk factors and
heart disease.
A large Canine study supports human findings. It was
found that shorter and smaller dogs have lower heart failure
than medium and large dogs.26 Based on 350,000 dogs, short
dogs had 1/60 the heart failure rate of tall dogs. Miller and
Austad27 provided similar findings.
Table 1 e Examples of short populations with low cardiovascular disease.
Example Remarks Reference
Shortest people in Sardinia had the lowest CVD mortality Based on 14 municipalities 13
Swedish study found men 191 cm had twice the mortality from CVD and respiratory disorders vs. men 170 cm 14
Six shorter populations had less than half the CHD mortality vs. six tallest Western European countries Both sexes
Based on millions of deaths
15
China’s CHD death rate was 1/10 that of taller North America and Australia Later part of 20th C 8
Guangzhou (Canton) had the lowest CHD in the world Later part of 20th C Males: 164 cm 8
S. European CHD rates were 1/3e1/2 the rates of taller N. Europeans 8
S. Italians have lower CHD death rates compared to taller N. Italians 8
Shorter rural blacks in S. Africa have low CHD vs. taller White population 8
The short Sami (Lapps) have exceptionally low CHD compared to the taller general population 8
Among low income US adults, the shortest have 39% lower risk of heart disease vs. tallest adults 16
Shorter men in Ushibuka, Japan had much lower death rates from CHD and stroke vs. the taller Tanushimaru Japanese 8
Shorter Native Americans have lower CVD mortality vs. taller Native Americans 17
Six European countries with lowest CHD were shorter than the six tallest countries in Western Europe 17
California Japanese and Chinese had w1/2 the CHD mortality of taller Whites and Blacks 1/4 million deaths for six
ethnic groups. Both sexes
18
California Latinos and Asian Indians had much lower CHD mortality vs. taller Whites & Blacks 17
Shortest US ethnic groups have the lowest CHD mortality Millions of deaths. Five ethnic groups 17
CHD was rare before urbanization People were taller after urbanization 17
Shorter Okinawan males had 1/4 the CHD mortality of taller mainland Japanese and 1/6 the mortality of taller US males 17
Many short populations with little or no CHD and stroke; e.g., Solomon and Cook islands, Congo pygmies,
Papua New Guinea, Tarahumara Indians, Yanomamo Indians, Fiji islands
Height range: less than 152e<165 cm
Data based on mid-20th C
17
Based on 16 populations, shorter men showed a lower CHD mortality trend Mid-20th century 18
Shorter Toulouse (France) had 1/4 the CHD mortality of taller Belfast (Ireland) males 18
Taller Hindu males in India had much higher CHD incidence and hypertension vs. shorter Muslim males in India Lower differences between females 18
Shorter native Japanese had lower CHD mortality vs. taller Hawaiian Japanese, and taller California Japanese
had higher CHD vs. shorter Hawaiian Japanese
18
Shorter Chinese had lower CHD mortality vs. taller Chinese Joint Chinese, US, & UK study 18,19
No evidence of CHD or stroke in Kitava (males: 162.6 cm), an island off Papua New Guinea Subjects 14e87 years of age 18
Taller affluent Pakistanis had 3 times the incidence of CHD vs. shorter poor people
Shorter women have substantially lower CHD mortality throughout the world 18
A longitudinal study found the risk of CHD in adulthood was lower for adults who were
short at 11 years vs. those who were tall
18
Shorter US Blacks had much lower heart disease vs. taller Whites before the 1930s. 15
WWI tall recruits had more heart disorders than shorter recruits Based on 1 million recruits 8
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A number of biological factors indicate that shorter, smaller
bodies have an inherently lower risk of CVD. These factors are
based on the assumption that tall and short people are of
similar body types.
3.3.1. Lower BP
Blood pressure (BP) tends to increasewith greater height, body
weight and BMI. A large US study found height was the
strongest factor affecting BP throughout childhood and
adolescence.28 Weight was also a strong factor. In addition,
adult BP was reported to correlate with BP in childhood,
adolescence and young adulthood. Thus, shorter, leaner
people are less likely to have elevated BP and are at lower risk
for CVD and stroke.
3.3.2. Lower workload per stroke
The hearts of shorter people are scaled to their body weight.
Thus, they have to pump an amount of blood in proportion to
their body volume. However, shorter people have an advan-
tage that their hearts do not have to pump blood as high as the
hearts of taller people. Taller people’s hearts have to work
harder in accordance with scaling laws29; e.g., a 10% taller
person of the same body proportions as a shorter person has
to pump 33% more blood 10% farther. Yet, the heart’s
maximum muscle strength is only 21% greater. Shorter
people, however, have a higher resting pulse rate. This may
not be a problem since small dogs, with their higher pulse
rates, have very low heart failure risk vs. larger dogs.26
3.3.3. Lower venous thromboembolism
In developed countries, venous thromboembolism (VTE) is
the third most common CVD illness. Shorter males were
found to have substantially lower VTE in a large Norwegian
study.30 A cohort of 26,727 subjects aged 25e96 years was
tracked over a 12.5 year period. Men in the upper height
quartile (>181 cm) had twice the risk of VTE compared to the
shortest quartile (<173 cm). However, tall (>167 cm) women
did not have a significant trend.
3.3.4. Lower left ventricular hypertrophy
Left ventricular hypertrophy (LVH) occurs when the heart’s
wall thickness increases without a corresponding increase in
heart volume. This condition increases the risk of CVD
morbidity and mortality.31 Based on a study of 4976 men and
women, Levy31 found a significant trend toward greater rates
of LVH in taller men and women without adjusting for body
size. After adjusting for body size, a sharp increase in LVH
occurredwith rising BMI, starting from<22 kg/m2 formen and
<20 kg/m2 for women; e.g., a 2 kg/m2 increase in BMI was
found to increase the prevalence of LVH by 47% in men and
51% in women.
Another possible advantage of a smaller heart is the
smaller size of myocytes. After the first year of life, increased
heart size occurs through cell enlargement rather than cell
replication. According to the laws of scaling,22 cell mass
increases at a faster rate than its surface area. As a result, the
supply of nutrients and oxygen through the cell membrane
(surface area) would be less than the mass being fed. Inaddition, removal of waste products and heat energywould be
similarly less efficient.
3.3.5. Lower atrial fibrillation
Atrial fibrillation (AF) involves an irregular heart beat pattern
that is correlated with increased risk of heart failure and
stroke. Hanna32 evaluated 25,268 patients with impaired left
ventricular dysfunction. They found that AF increased linearly
with increasing height. There was a 32% increase between
short and tall subjects with a p < 0.0001. Height is correlated
with left atrial (LA) size and is the strongest independent
predictor of AF. Taller height also correlated with AF inde-
pendent of other risk factors.
3.3.6. Greater cell replicative capacity and longer telomeres
reduce CHD
Within a species, the remaining capacity of cells to reproduce
is tied to chronological age.33 Maier found that shorter elderly
people had greater cell replicative capacity compared to taller
people. This reduced capacity of taller people is due to a higher
number of cell doublings during the growth period and
greater cell replacement and maintenance over the adult
lifespan. In addition, larger men had a lower replicative
capacity compared to women although men and women had
the same replication potential at birth.
Telomeres tie the ends of chromosomes together. When
cells replicate, telomeres get shorter and their lengths are
markers for the number of future cell replications possible. A
number of studies have found that aging of the cardiovascular
system is connected to telomere shortening.34 In addition,
Brouilette35 found that shorter telomeres almost doubled the
risk of CHD compared to the longest telomeres.
3.3.7. Lower DNA damage
Giovannelli36 found that taller men had much higher DNA
oxidative damage than shorter men (p ¼ 0.02). The shortest
men and women had a damage level of 3.28% vs. 6.08% for the
tallest people. Less damage to the DNA of the heart muscle
cells during one’s lifetime may help maintain heart-pumping
capability.37e39 In addition, with slower childhood growth,
resources are less likely to be diverted in favor of rapid growth
and taller stature, resulting in improved repair of DNA and
other cellular components.
3.3.8. Higher pumping efficiency
Higher heart pumping efficiency increases the supply of
oxygen and nutrients per kilogram of body mass. Smaller
hearts have a higher pumping efficiency compared to larger
hearts.40 De Simone found that heart size correlates with
height, and taller people have a lower pumping efficiency.
For normotensive adults, stroke volume and cardiac output
increased at a lower rate with increase in height than with
increase in weight (in proportion to the power of 0.71). Thus,
both stroke volume and cardiac output do not keep up with
body size of a taller person.
3.3.9. Lower cystatin C, lower creatinine and higher SHBG
Knight41 reported that cystatin C and creatinine levels corre-
late with height andweight. However, higher levels of cystatin
C and creatinine are associated with greater CVD risk factors.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 6e7 170Chen19 found that Sex Hormone Binding Globulin (SHBG)
decreases with increasing height. In addition, their findings
indicate that lower SHBG levels are correlated with increased
mortality from stroke, hypertensive heart disease, myocardial
infarction and coronary heart disease.
3.3.10. Shorter people have lower BMIs, cholesterol,
triglycerides, and higher HDL
If short and tall people of the same body proportions are
compared, the taller people will have higher BMIs based on
empirical evidence and the laws of scaling.29 For example, if
we compare a 10% taller person to a shorter person, the BMI
will be 10% greater than that of the shorter person with the
same body proportions.
Lamon-Fava42 found that biological parameters related to
CHD became worse with increasing BMI from below 21 to
a BMI over 30. Changes in these parameters were age adjusted
and increased linearly in middle-aged nonsmoking men and
women. They found that as BMI increased, systolic blood
pressure, cholesterol, triglycerides, glucose, and low-density
lipoprotein increased while desirable levels of HDL and Apo
A-1 decreased. Hypertension, type 2 diabetes and Apo B also
increased. Mendall20 also found C-reactive protein increased
with both height and BMI. All these factors have been related
to increased risk of CVD.
3.3.11. Heart advantages of taller people
Taller people have a few heart advantages. Taller people have
a lower resting heart rate compared to shorter people. A lower
heart rate is generally associated with a longer functioning
heart. In addition, larger diameter arteries are less likely to
develop plaque build up on the Western diet. However, the
previous discussion of Solomon andKitava islanders indicates
that if these are desirable factors, other aspects of being small
offset the disadvantages of a higher heart rate and smaller
blood vessels.4. Discussion
Inviewof substantial contraryfindingsonheightandCVD,why
are there such strong differences among studies? Tuomilehto2
pointed out that short stature is tied to lower socioeconomic
status (SES) and lowerSES is related to increasedCHD.Since it is
not short height per se that explains why shorter people in
developed countries have more CVD, environmental and life-
style factors must be the cause. These include differences in
SES status, nutrition,medical care, lifestyle practices (smoking,
lack of exercise, excessive drinking), and catch-up growth of
low birth weight infants. Singhal,43 Monteiro and Victora44 and
Bartke45 have reported that low birth weight children that are
overfed to accelerate their growth (catch-up growth) experi-
ence increased risk of heart disease and other chronic diseases.
It should be noted that this catch-up growth does not normally
result in low birth weight children catching up to the height of
their adult peers who were of normal birth weight. Lower SES
adults also tend to be shorter, more obese and less healthy
compared to higher SES people.
Evaluation of CVD among short individuals needs to
consider the following.1. SES risk factors over three phases of life.46e48 Evaluating
only one or two SES phases can provide misleading results.
2. The role of dietary factors; e.g., during the lean years ofWW
II, Europeans experienced a drastic reduction in CVD.49
3. Incorrect association of short height with adult disease
when the shorter height is due to childhood disease; e.g.,
w50% of short children suffer from pathological conditions
and childhood illnesses increase the risk of adult chronic
disease.
4. Are tall and short people with the same body types being
compared?29
5. Conclusions
The findings of this paper indicate that shorter height appears
to be an advantage for avoiding CVD under traditional life-
styles. This finding is consistent with Bartke’s gerontological
review that smaller body size is related to greater longevity.50
However, short people following a Western diet and poor
health habits are at increased risk due to high fat, calorie diets
and excessive weight. Promoting catch-up growth or taller
stature during childhood also increases risk. Therefore,
shorter people need to focus on keeping lean and following
a healthful lifestyle and a plant-based diet.Conflicts of interest
The author has none to declare.r e f e r e n c e s
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